The U.S. administration has announced plans to implement a 25% tariff on imported medical technologies (MedTech), pharmaceuticals, and automobiles, set to take effect today, April 2, 2025. This significant policy shift will undoubtedly impact the MedTech industry, requiring companies to adapt their strategies to mitigate the financial burden. Considering recent political instability, it's crucial to reassess and optimize your supply chain and manufacturing processes.
RQM+ is a Pennsylvania-based CRO that provides services such as clinical trials, polymer investigation, billing and strategy development for the medical industry.